In this free webinar, learn about the challenges, opportunities and advances in the development of CAR T-cell therapies for solid tumors. Attendees will gain insights into progress in expanding the indications and applicability of CAR T-cell therapies in hematological malignancies, such as use in earlier lines of treatment or in combination with other treatments. The featured speaker will discuss approaches to improving the safety, efficacy and cost of CAR T-cell therapies, including bi-specific chimeric antigen receptors (CARs), multi-antigen-targeted therapies, controlled CARs and allogeneic treatments. The speaker will also share strategies for enhancing the patient-centricity of CAR T-cell trials and best practices for toxicity management.
TORONTO, March 2, 2023 /PRNewswire-PRWeb/ -- CAR T-cell therapies have transformed the therapeutic landscape for hematologic malignancies, offering substantial benefit to patients with few alternative treatment options. While these innovative therapies represent a breakthrough in immuno-oncology, their impact thus far has been limited to a small subset of patients, and challenges to development and commercialization remain a hurdle. These challenges range from narrow patient eligibility criteria and complex administration processes to off-tumor toxicity, complicated manufacturing scale-up and high costs.
There is significant potential to expand the applications of — and broaden access to — CAR T-cell therapies to address unmet needs. Opportunities exist to not only optimize the safety, efficacy and clinical potency of these treatments, but also make them more widely available to larger, more diverse patient populations.
Join the featured speaker as they explore key strategies for broadening access to CAR T-cell therapies and discuss important considerations for sponsors focused on increasing patient-centricity and diversity in clinical trials involving these novel treatments.
Join Ayesha A. Pandit, MD, MS, MBA, Vice President, Medical Affairs, Premier Research, for the live webinar on Thursday, March 23, 2023, at 11am EDT (4pm CET/EU-Central).
For more information, or to register for this event, visit CAR T-Cell Therapies: Extending Hope with Broadened Access.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article